Literature DB >> 18996815

A patient with hypophosphatemia, a femoral fracture, and recurrent kidney stones: report of a novel mutation in SLC34A3.

Kathleen Page1, Clemens Bergwitz, Graciana Jaureguiberry, Chittari V Harinarayan, Karl Insogna.   

Abstract

OBJECTIVE: To determine if there was a genetic contribution to our patient's unusual clinical presentation of nephrolithiasis and nonhealing stress fracture.
METHODS: We describe a 31-year-old man who had rickets as a child and developed a femur insufficiency fracture and recurrent nephrolithiasis as an adult after moving to the United States from India. The patient's clinical course and results from radiographic and biochemical analyses are described. Analysis of the SLC34A3 gene was performed using genomic DNA samples from the patient and his family members.
RESULTS: Before referral to the Yale Bone Center, the patient was treated with calcitriol, ergocalciferol, and phosphate. Changing therapy to phosphate alone led to clinical improvement. Genetic analysis revealed that the patient is a compound heterozygote for mutations in the SLC34A3 gene. On 1 allele, he has a previously described missense mutation in exon 7: c.575C>T (p.Ser192Leu). The other allele carries a novel nonsense mutation in exon 3: c.145C>T (p.Gln49X). One unaffected sibling is a carrier of the missense mutation and 1 sister with a history of flank pain is a carrier of the novel mutation.
CONCLUSIONS: Hereditary hypophosphatemic rickets with hypercalciuria is a rare metabolic disorder associated with mutations in SLC34A3, the gene that encodes the renal sodium phosphate cotransporter NaPi-IIc. Although hypercalciuria is a distinguishing feature of the disease, nephrolithiasis is rarely described. The patient's atypical clinical presentation illustrates that both environmental and genetic factors potentially affect phenotypic expression of SLC34A3 mutations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18996815      PMCID: PMC2773288          DOI: 10.4158/EP.14.7.869

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  10 in total

1.  Nomogram for derivation of renal threshold phosphate concentration.

Authors:  R J Walton; O L Bijvoet
Journal:  Lancet       Date:  1975-08-16       Impact factor: 79.321

2.  Hereditary hypophosphatemic rickets with hypercalciuria.

Authors:  M Tieder; D Modai; R Samuel; R Arie; A Halabe; I Bab; D Gabizon; U A Liberman
Journal:  N Engl J Med       Date:  1985-03-07       Impact factor: 91.245

3.  SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis.

Authors:  Clemens Bergwitz; Nicole M Roslin; Martin Tieder; J C Loredo-Osti; Murat Bastepe; Hilal Abu-Zahra; Danielle Frappier; Kelly Burkett; Thomas O Carpenter; Donald Anderson; Michele Garabedian; Isabelle Sermet; T Mary Fujiwara; Kenneth Morgan; Harriet S Tenenhouse; Harald Juppner
Journal:  Am J Hum Genet       Date:  2005-12-09       Impact factor: 11.025

4.  Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3.

Authors:  Bettina Lorenz-Depiereux; Anna Benet-Pages; Gertrud Eckstein; Yardena Tenenbaum-Rakover; Janine Wagenstaller; Dov Tiosano; Ruth Gershoni-Baruch; Norbert Albers; Peter Lichtner; Dirk Schnabel; Ze'ev Hochberg; Tim M Strom
Journal:  Am J Hum Genet       Date:  2005-12-09       Impact factor: 11.025

5.  Increased circulating concentrations of parathyroid hormone in healthy, young women consuming a protein-restricted diet.

Authors:  J E Kerstetter; D M Caseria; M E Mitnick; A F Ellison; L F Gay; T A Liskov; T O Carpenter; K L Insogna
Journal:  Am J Clin Nutr       Date:  1997-11       Impact factor: 7.045

6.  Intronic deletions in the SLC34A3 gene cause hereditary hypophosphatemic rickets with hypercalciuria.

Authors:  Shoji Ichikawa; Andrea H Sorenson; Erik A Imel; Nancy E Friedman; Joseph M Gertner; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2006-07-18       Impact factor: 5.958

7.  Hyperoxaluria is not a cause of nephrocalcinosis in phosphate-treated patients with hereditary hypophosphatemic rickets.

Authors:  M Tieder; J Blonder; S Strauss; U Shaked; J Maor; D Gabizon; H Manor; B A Sela
Journal:  Nephron       Date:  1993       Impact factor: 2.847

8.  Oxalate absorption and postprandial urine supersaturation in an experimental human model of absorptive hypercalciuria.

Authors:  S B Erickson; K Cooper; A E Broadus; L H Smith; P G Werness; H J Binder; J W Dobbins
Journal:  Clin Sci (Lond)       Date:  1984-07       Impact factor: 6.124

9.  Bone resorption stimulated by elevated serum 1,25-(OH)2-vitamin D concentrations in healthy men.

Authors:  W J Maierhofer; R W Gray; H S Cheung; J Lemann
Journal:  Kidney Int       Date:  1983-10       Impact factor: 10.612

10.  Osteomalacia in hereditary hypophosphatemic rickets with hypercalciuria: a correlative clinical-histomorphometric study.

Authors:  D Gazit; M Tieder; U A Liberman; L Passi-Even; I A Bab
Journal:  J Clin Endocrinol Metab       Date:  1991-01       Impact factor: 5.958

  10 in total
  12 in total

Review 1.  Hereditary disorders of renal phosphate wasting.

Authors:  Amir S Alizadeh Naderi; Robert F Reilly
Journal:  Nat Rev Nephrol       Date:  2010-10-05       Impact factor: 28.314

2.  Novel NaPi-IIc mutations causing HHRH and idiopathic hypercalciuria in several unrelated families: long-term follow-up in one kindred.

Authors:  Y Yu; S R Sanderson; M Reyes; A Sharma; N Dunbar; T Srivastava; H Jüppner; C Bergwitz
Journal:  Bone       Date:  2012-02-24       Impact factor: 4.398

Review 3.  Genetics of Refractory Rickets: Identification of Novel PHEX Mutations in Indian Patients and a Literature Update.

Authors:  Binata Marik; Arvind Bagga; Aditi Sinha; Pankaj Hari; Arundhati Sharma
Journal:  J Pediatr Genet       Date:  2018-01-28

Review 4.  Renal phosphate handling and inherited disorders of phosphate reabsorption: an update.

Authors:  Carsten A Wagner; Isabel Rubio-Aliaga; Nati Hernando
Journal:  Pediatr Nephrol       Date:  2017-12-23       Impact factor: 3.714

5.  Evidence for a role of PDZ domain-containing proteins to mediate hypophosphatemia in calcium stone formers.

Authors:  Kristin J Bergsland; Fredric L Coe; Joan H Parks; John R Asplin; Elaine M Worcester
Journal:  Nephrol Dial Transplant       Date:  2018-05-01       Impact factor: 5.992

6.  Late-onset hereditary hypophosphatemic rickets with hypercalciuria (HHRH) due to mutation of SLC34A3/NPT2c.

Authors:  Gauri Dhir; Dong Li; Hakon Hakonarson; Michael A Levine
Journal:  Bone       Date:  2016-12-07       Impact factor: 4.398

7.  Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosis.

Authors:  Debayan Dasgupta; Mark J Wee; Monica Reyes; Yuwen Li; Peter J Simm; Amita Sharma; Karl-Peter Schlingmann; Marco Janner; Andrew Biggin; Joanna Lazier; Michaela Gessner; Dionisios Chrysis; Shamir Tuchman; H Jorge Baluarte; Michael A Levine; Dov Tiosano; Karl Insogna; David A Hanley; Thomas O Carpenter; Shoji Ichikawa; Bernd Hoppe; Martin Konrad; Lars Sävendahl; Craig F Munns; Hang Lee; Harald Jüppner; Clemens Bergwitz
Journal:  J Am Soc Nephrol       Date:  2014-04-03       Impact factor: 10.121

Review 8.  Hereditary hypophosphatemic rickets with hypercalciuria: pathophysiology, clinical presentation, diagnosis and therapy.

Authors:  Clemens Bergwitz; Ken-Ichi Miyamoto
Journal:  Pflugers Arch       Date:  2018-08-14       Impact factor: 3.657

9.  HYPOPHOSPHATEMIC RICKETS WITH HYPERCALCIURIA: A NOVEL HOMOZYGOUS MUTATION IN SLC34A3 AND LITERATURE REVIEW.

Authors:  Sanjay K Bhadada; Subbiah Sridhar; Vandana Dhiman; Karen Wong; Bruce Bennetts; Dorit Naot; Sangumani Jayaraman; Tim Cundy
Journal:  AACE Clin Case Rep       Date:  2020-05-11

10.  Hypophosphatemic rickets.

Authors:  Varsha S Jagtap; Vijaya Sarathi; Anurag R Lila; Tushar Bandgar; Padmavathy Menon; Nalini S Shah
Journal:  Indian J Endocrinol Metab       Date:  2012-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.